WHIPPANY, N.J., May 2, 2017 /PRNewswire/ -- Bayer today announced the appointment of Bhavesh Ashar as senior vice president and head of Oncology for the company's Pharmaceuticals Division in the United States. Ashar will report to Carsten Brunn, Head of Bayer Pharmaceuticals for the Americas region.
"Bhavesh is a well-respected, results-driven leader with extensive industry knowledge and a proven track record of launching products and driving growth in oncology," said Brunn. "We are delighted to have Bhavesh join Bayer's U.S. Pharmaceuticals organization. I'm confident that he will help to advance our growing leadership in oncology and our ongoing commitment to meeting the needs of people living with cancer."
Previously, Ashar served as vice president and general manager of U.S. Oncology at Sanofi and was responsible for managing a diverse portfolio comprising solid tumor, hematology and transplant products. Ashar was with Sanofi for more than 14 years and held positions of increasing responsibility in sales and marketing, with a strong focus on specialty markets. Prior to joining Sanofi, Ashar served as an engagement manager with McKinsey & Company.
Bayer's diverse oncology portfolio and pipeline is helping to address some of the most difficult to treat cancers in areas of high unmet need. The oncology franchise includes three marketed products and several other compounds in various stages of clinical development.
"Oncology is a critical growth driver for Bayer and I am excited to help the company realize the full potential of its diverse cancer portfolio," said Ashar.
Ashar holds a Bachelor of Science degree in Mathematics from Imperial College in London and an MBA from the University of Chicago Booth School of Business.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
© 2017 Bayer
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Intended for U.S. Media Only